Brain Cancer Clinical Trials in Seattle

Showing 61-80 of 93 trials

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

NCT01125046

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Acoustic SchwannomaAdult Anaplastic MeningiomaAdult Ependymoma+7 more

Northwestern University50 participantsStarted Jun 2010

Chicago, Illinois, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 2< 1 mile

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

NCT02343406

This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.

Glioblastoma

AbbVie266 participantsStarted Feb 2015

Palo Alto, California, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +99 more locations

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Brain Cancer Trials in Other Cities

ANG1005 in Patients With Recurrent High-Grade Glioma

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Radiation Therapy in Treating Young Patients With Gliomas

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Gliogene: Brain Tumor Linkage Study

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Other Conditions in Seattle